Clinical Trial Update: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating metabolic mechanisms of ertugliflozin in patients with diastolic heart failure and type 2 diabetes was terminated; results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Type 2 Diabetes Mellitus

Drugs mentioned

• Ertugliflozin (ertugliflozin)

Snippet

Sponsor: University Hospitals Cleveland Medical Center | Conditions: Heart Failure, Diastolic, Diabetes Mellitus, Type 2 | Phase 4 | Status: TERMINATED | Results posted: 2023-12-13